MicroRNAs (miRNAs) play pivotal roles in stem cell biology, differentiation and oncogenesis and are of high interest as potential breast cancer therapeutics. However, their expression and function during normal mammary differentiation and in breast cancer remain to be elucidated. In order to identify which miRNAs are involved in mammary differentiation, we thoroughly investigated miRNA expression during functional differentiation of undifferentiated, stem cell-like, murine mammary cells using two different large-scale approaches followed by qPCR. 
Introduction
In the clinic, breast cancer is classified into different subtypes depending on the expression of three receptors, the estrogen (ERα), progesterone (PR) and Her2 receptors. Additional subtypes can be classified using molecular profiling (1) , and most triple-negative breast cancers belong to the basal-like subtype. Targeted treatments against ERα or PR or Her2 positive tumors are available. Triple-negative breast tumors, defined by a lack of expression of these receptors, relapse faster than other types of breast cancer and have a higher prevalence among younger women. Despite a high mortality rate, few effective treatment options currently exist for this diagnosis. Current research into breast cancer treatment is aimed at designing disease subtypespecific treatments. The first critical step is to identify a suitable target. Small non-coding RNAs have emerged as major gene expression regulators. There is an increasing body of evidence showing that microRNAs (miRNAs) play pivotal roles in stem cell biology, differentiation and oncogenesis (2) . Tumor suppressor or oncogenic miRNAs have been described, and dysregulation in their expressions causes tumorigenesis (3, 4) . Their small size and their potential to target multiple pathways simultaneously make them promising candidates for cancer therapeutics (5) (6) (7) . In order to exploit miRNAs for breast cancer therapy, an in-depth understanding of their normal expression and function is essential. How miRNAs impact mammary differentiation or mammary stem cell characteristics have not been thoroughly defined.
Reports have compared fluorescence-activated cell sorting-enriched normal mammary stem cells from the mouse mammary gland and human fluorescence-activated cell sorting-enriched breast cancer stem cells (CSC) from clinical tumors with remaining breast cancer cell populations (8) . Others have studied enriched CSC populations of MCF-7 breast cancer cells (9) or Sca-1+ populations of the mouse mammary epithelial progenitor cell line, Comma-D (10, 11) . Some discrepancies exist between the different studies, possibly related to the characteristics of the cell line(s) or cell populations used, and no large-scale correlation of differentiation-regulated miRNAs in mammary cells, and their relation to transcriptome changes has been performed. To thoroughly characterize the miRNAs that may be involved in maintaining an undifferentiated mammary phenotype or in inducing terminal differentiation, we took advantage of the HC11 non-tumorigenic murine mammary epithelial cell line. HC11 cells approximate both self-renewal and bipotency and can be cultured for an unlimited number of passages in a proliferating undifferentiating phase. They have the capacity to enter terminal differentiation, indicated by their ability to express milk proteins in vitro (12) . Illustrative of their stem cell abilities, HC11 cells can reconstitute the ductal epithelium of a cleared mammary fat pad in vivo with ductal, alveolar and myoepithelial cells (12, 13) . We have shown previously that the undifferentiated stage of HC11 cells share conserved, overlapping transcriptome signatures with poor-prognosis and basal-like breast cancer, suggesting relevance for this model in mammary stem cell and breast cancer-related studies (14) . We here describe the identification of a set of miRNAs with roles in mammary differentiation that we suggest are therapeutically useful.
Material and methods
Cell culture HC11 mammary epithelial cells were grown in RPMI 1640 supplemented with 10% fetal bovine serum, l-glutamine, 5 mg/ml insulin, 10 ng/ml epidermal growth factor (EGF) and 50 mg/ml gentamicin; all cell culture reagents were purchased from Sigma. Proliferating cells were collected under the same conditions. Predifferentiated and fully differentiated HC11 cells were acquired sequentially after induction of differentiation as described previously (14) . In short, predifferentiation was induced by the removal of EGF from the medium and lowering of fetal bovine serum to 2% for 48 h. Full differentiation was accomplished through the subsequent addition of 100 nM dexamethasone and 1 µg/ml ovine prolactin for 72 h.
RNA extraction
Total RNA, including miRNA, was extracted using Trizol precipitation and purified using Qiagen miRNeasy kit followed by an on-column DNase1 digestion (Qiagen, Valencia, CA). Quantitative and qualitative analysis of RNA was performed on the NanoDrop 1000 spectrophotometer (Thermoscientific) and the Agilent 2100 bioanalyzer (Agilent), respectively. miRNA profiling analysis miRNA expression profiles of proliferating and differentiated cells were determined in three independent differentiation assays. Two different large-scale profiling methodologies, miRNA microarrays and TaqMan® Low-Density Array (TLDA), were applied to eliminate shortcomings of each technique. The miRNA microarray contained 700 unique probes and 49 controls with replicates. TLDA enabled the quantification of 468 unique mouse miRNAs (335 in card A and 133 in card B) along with three endogenous and negative controls. miRNA microarray. Mouse miRNA two color dual-sample arrays based on Sanger miRBase release 14.0 (LC-Sciences, Houston, TX) were used to determine the miRNA profile between undifferentiated and differentiated cells. Five milligrams of total RNA per sample were used for each microarray. Experiments were performed in duplicate with dye swap design. miRNAs were determined as potentially regulated when P < 0.1, according to the manufacturer's recommendation.
TLDA. miRNA expression profiles of two differentiation assays were compiled using TaqMan ® Rodent MiRNA A + B Cards Set v2.0 according to the manufacturer's protocol without the preamplification step (Applied Biosystems, Foster City, CA) using 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA). In short, 1 µg of total RNA, including the miRNA population, was used to perform the reverse transcription reaction in total volume of 7.5 microliters, and 6 microliters of reverse transcription product were used to perform real-time PCR. miRNAs were considered differentially expressed if in both replicates fold change >1.3 or <0.7, respectively. miRNAs that were determined regulated by both microarray and TLDA were validated using qPCR. In addition, a selection of miRNAs, whose probes were present only in one of the large-scale platforms and showed regulation in both replicates, were added to the qPCR analysis (Supplementary Data 1-4 and  Supplementary Tables 1-2 are available at Carcinogenesis Online).
cDNA synthesis and real-time PCR for miRNA and mRNA analysis For miRNA analysis, 1 mg of isolated total RNA per sample was polyadenylated using Ncode miRNA First-Strand cDNA Synthesis Kit (Invitrogen). Subsequent first strand cDNA synthesis was performed immediately using Superscript III and universal reverse transcription primers according to manufacturer's protocol (Invitrogen). SYBR-Green qPCR SuperMix (Applied Biosystems, Foster City, CA) was used for real-time qPCR with 16 ng of cDNA, 2 pmol of universal qPCR primer and 2 pmol of miRNA-specific forward primer per 10 µl of final reaction volume. All SYBR-Green amplifications were checked with melting curve analysis. Only amplifications with one defined melting curve were used for further analysis. TaqMan miRNA assays were used for miRNAs that could not be specifically amplified using SYBR-Green technology. The two-step assay was carried out according to manufacturer's protocol (Applied Biosystems, Foster City, CA) and 10 ng total RNA was used per cDNA synthesis. For mRNA analysis, cDNA was synthesized using Superscript III (Invitrogen) and random hexamer primers as described previously (14) . All performed SYBR-Green qPCR amplifications were checked with melting curve analysis. Primer sequences are provided on request. Both SYBR-Green and TaqMan miRNA assays were performed using ABI PRISM 7500 (Applied Biosystems, Foster City, CA) and fold changes were calculated using the ∆∆CT formula. U6 snRNA was used as the reference gene for all miRNAs, whereas glyceraldehyde 3-phosphate dehydrogenase and 18S were used for mRNA qPCRs. Unpaired two-tailed t-tests were used to compare differences between two parallel treatment groups of identical origin. Significance is presented as *P < 0.05, **P < 0.01, or ***P < 0.001.
Indirect immunofluorescence and image acquisition
Immunostaining was carried out on cells grown on permanox two-well chamber slides (Nunc) and transfected as described below. Following 24-h treatment, cells were fixed in 4% buffered formalin for 20 min and permeabilized with 0.5% Triton X-100 for 10 min. After several washes with phosphate-buffered saline, unspecific binding was blocked with 15% fetal bovine serum in 0.1% Tween 20-phosphate-buffered saline and E-cadherin staining was carried out over night with a mouse anti-E-cadherin antibody (BD Transduction Labs), followed by antimouse Alexa 488 antibody (Invitrogen). The slides were mounted in ProGold anti-fade medium (Molecular Bioprobes). Images were acquired using the same settings and when edited with Adobe Photoshop 6.0, the same adjustments were applied to all images.
Bioinformatics
Ariadne Pathway Studio was used for analysis of networks and pathways. Fischer's exact test is applied to define enriched Gene Ontology functional groups among the differentially expressed genes. Results were considered statistically significant for P ≤ 0.05. The Sub-Network Enrichment Analysis algorithm was used to define overrepresented subnetworks. Results were considered statistically significant for P ≤ 0.05. Values are expressed as means with 95% confidence intervals. TargetScan was employed to predict targets of differentially expressed miRNAs, and the regulation of target genes via cell differentiation is obtained by comparison with the genome-wide mRNA analysis.
Survival cluster analysis
To analyze the effect of undifferentiated HC11 gene signature in breast cancer patient samples, the list of significant murine genes from the HC11 cell studies were matched to their human orthologs. Expression profiles of these genes were then used to group 258 clinical, untreated, primary breast cancer samples from a patient cohort from Uppsala, Sweden (15) , by hierarchical clustering (Eisen Cluster and TreeView). Disease-free survivals of the two patient groups were graphed using the Kaplan-Meier plot function in the SigmaPlot software, and associations with disease parameters (ERα/PR status, lymph node positivity, tumor grade, recurrence, distant metastasis, death) were calculated using the Fisher's exact test.
miRNA mimic transfections HC11 cells were transfected with miRIDIAN miRNA Mimic (Dharmacon, Lafayette, CO). A Dy547-labeled transfection control was used to determine optimal conditions and visualize transfection efficiency. Images were taken 24 h after transfection initiation. Cell density and transfection agent (Dharma-FECT 1) concentrations were optimized for HC11 cells: 5000 cells/well and 300 000 cells/well in 96 and 6 well plates, respectively. All mimic and control transfections were then performed using 25 nM final concentration of mimic and 0.1% DharmaFECT 1. qPCR analysis of direct and downstream target genes was performed 24 h posttransfection.
Results
Molecular mechanisms involved in stem cell maintenance or differentiation frequently play important roles in cancer development. In this study, we aimed to identify the miRNA subsets that are selectively expressed in undifferentiated mammary epithelial cells compared with their functionally differentiated counterparts. The model we used, the HC11 cell line, is a non-tumorigenic, undifferentiated mammary epithelial cell line that originates from BALB/c mice in mid-pregnancy (12) . Mid-pregnancy is a period of mammary stem cell expansion (16) . These cells also possess a mutation in the p53 gene, potentially further increasing the replicative potential of stem cells (17) . In addition, the p53 mutation confers Li Fraumeini characteristics and a predisposition to mammary carcinoma. The stage that comprises undifferentiated cells exhibits stem cell characteristics and shares a gene signature with stem cells (14), we therefore refer to this stage as 'stem cell-like' (SC-like) in this study. We have previously defined the exact gene expression profiles of HC11 cells for each differentiation stage (14) . In order to investigate the expression and roles of miRNAs in the corresponding differentiation stages, we used the approach presented in Figure 1A .
HC11 murine mammary epithelial cells showed complete and robust differentiation pattern
To identify changes in miRNA expression, we prepared three replicates of HC11 cell differentiation experiments. Each replicate's appropriate differentiation stage was confirmed using previously defined markers (14) as exemplified in Figure 1B -D. Expression indicative of the undifferentiated stage of these cells including a high level of Melk ( Figure 1A and B) that is also highly expressed in breast CSCs (18) , and a high level of Birc5 ( Figure 1C ), an inhibitor of apoptosis. The fully differentiated cells showed high expression of, for example, Figure 5 ), have a significantly higher rate of high-grade tumors, ERα negativity, lymph node positivity, recurrence, distant metastasis and death.v miRNAs in mammary cell differentiation epithelium-specific Ets-domain-containing transcription factor, Ehf ( Figure 1D ). In addition, beta-casein protein is expressed in the fully differentiated stage ( Figure 1A) . These results clearly demonstrate the robust and reproducible gene regulation during the induced differentiation of HC11 cells.
miRNAome was regulated during differentiation
The distinct transcriptional changes observed during the differentiation of HC11 cells made it plausible to assume that the same approach could detect corresponding changes in miRNA levels. The short length (~22 nt) of mature miRNAs and the additional presence of pri-/pre-miRNAs make miRNA analysis less straightforward than conventional mRNA analysis. To identify changes in the miRNAome, we used two complementary large-scale screening techniques: miRNA microarrays and TLDA. We investigated the changes in miRNA expression between the undifferentiated SC-like stage and the fully differentiated stage (Supplementary Tables 1-2 are available at Carcinogenesis Online). Indicated changes were further analyzed using qPCR in the three different stages of differentiation: SC-like, predifferentiated and fully differentiated, in three replicated differentiation experiments. We identified and confirmed significant regulation of 21 miRNAs during the differentiation as illustrated in Figure 3E . miR-200b-transfected cells showed more epithelial morphology, the cells tend to group together forming more tightly packed clusters and show a clearer polyhedral morphology compared with negative control. The finding that miR-200a and miR200b can be used to inhibit EMT characteristics in undifferentiated, highly migratory HC11 cells is of significant therapeutic importance.
EphA2 mRNA is downregulated by miR-200a expression miR-200a was found to be the most highly regulated miRNA in our study. It has a known role in targeting Zeb1, Zeb2 and Suz12 and thereby affecting EMT in mammary cells. However, miRNAs usually target multiple genes and it is possible that miR-200a has additional roles. When miRNAs form duplexes with the 3ʹ untranslated region end of their target mRNAs, they inhibit the translation of these genes and frequently also degrade the targeted mRNA (23) . Given this, we used our previously defined HC11 transcriptome data (14) in combination with bioinformatic predictions to characterize putative miRNA:mRNA functional pairs (Supplementary Table 3 , available at Carcinogenesis). This led to the prediction that miR-200a targets the ephrin receptor of the protein-tyrosine kinase family (EphA2). EphA2 has been shown to regulate mammary gland branching (24) and to promote mammary tumorigenesis and metastatic progression in mice (25, 26) . During differentiation of the HC11 cells, the mRNA level of EphA2 was downregulated concomitant with the upregulation of miR200a ( Figure 3C and Figure 2B ). Using miR-200 mimics, we showed that miR-200a, but not miR-200b, expression downregulated EphA2 in transfected HC11 cells ( Figure 3D ). That EphA2 is downregulated as a consequence of miR-200a expression is a novel finding with major clinical implications.
Stem cell and oncogenic networks are targeted by regulated miRNAs
The low miR-200a/miR-200b expression in the SC-like stage correlates with reports of the miR-200 family being downregulated in both normal and breast CSCs (8, 9) . Their overexpression has been shown to block formation of mammospheres in both human and murine cells (20) and to suppress expression of stem cell factors (27) , indicative of an ability to inhibit parallel stem cell mechanisms. We assumed that these and the remaining identified miRNAs play additional roles during differentiation and used bioinformatic approaches to generate an overview of such potential interactions. This allowed the construction of an integrated network of genes and miRNAs regulated during HC11 cell differentiation, and their known functions as reported in literature. These networks were then screened for overrepresented biological pathways and interactions. Figure 4 and Supplementary Figure 1 (available at Carcinogenesis Online) illustrate identified overrepresented pathways, the Wnt, Stat and E2F-pathways. 
miRNAs in mammary cell differentiation
We note that many of the differentiation-induced miRNAs are considered tumor suppressors (28) . These includes the let-7 family, which is downregulated in cancer cells and further downregulated in CSCs (5, 20) , and the 80-fold upregulated miR-146b ( Figure 2B ), which has been reported to suppress breast cancer metastasis (29) . Our network analysis indicated that several of the differentiation stage miRNAs (e.g. miR-148a, miR-200b, miR-27b, miR-205 and miR-146a/b) target different oncogenes (Met, Ran, Maff and Dek). In addition, miR-200b targets several members of pathways with essential roles in stem cell self-renewal. We predicted targets in the Wnt, Hedgehog and Notch signaling pathways (Prkca, Met and Lfng, all subsequently downregulated during differentiation, Supplementary Table 3, available at Carcinogenesis Online). Figure 4A illustrates an intricate network of Wnt and stem cell-related genes, oncogenes and miRNA interactions inferred from the gene expression analysis and bioinformatic predictions. Members of the Wnt pathway are targeted by miR-30b, miR-200b and miR-148a. Myc, which interacts with Wnt, is also affected through multiple pathways involving miRNAs miR-30b/d, miR-205 and miR-200b. Further, a downstream product of Wnt signaling activation, Serpine1, is targeted by both miR-148a and miR-181a, and numerous genes affecting Serpine1 expression are simultaneously targeted by several miRNAs (including miR-148a, miR-27b, miR-200b, miR-205, miR-26a and miR-181a). Serpine1 is a member of the serine proteinase inhibitor family, which are reported stem cell markers (30) , and was found to be highly expressed in the SC-like stage of the HC11 cells ( Figure 4C ). This illustrates how multiple differentiation-induced miRNAs can work together in targeting connected pathways implicated in breast cancer.
We also note known oncomiRs among the four miRNAs upregulated in the SC-like stage. miR-17 is a potential oncomiR in several cancers (31) and miR-206 has been shown to contribute to abrogation of estrogenic responses in breast cancer cells and to contribute to a basal-like phenotypic switch (32) . We predict miR-17 to target the tumor suppressor genes Dab2 and Celsr2. These genes were upregulated during differentiation (14) concomitant with miR-17 downregulation. Dab2 is a putative tumor suppressor that inhibits proliferation in ovarian Immunoflouresence staining of E-cadherin in miR-200b-transfected HC11 cells. miR-200b expression led to a more epithelial morphology and where cells tended to group together forming more tightly packed clusters, it led to a clearer polyhedral morphology compared with negative control. *P < 0.05, **P < 0.01 and ***P < 0.001.
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cancer (33) , negatively regulates Wnt signaling (34) , and is needed for embryonic stem cell differentiation (35) . This gene has not previously been reported as having a role in mammary differentiation or breast cancer. In addition, we predict that miR-17 targets both Stat3 and the Stat3-regulated gene Pik3r1 ( Figure 4B ). The Stat3 pathway has been observed to be transcriptionally downregulated in the SC-like stage (14) . Although activation of Stat3 through phosphorylation is required for self-renewal of embryonic stem cells, we note that its transcript is downregulated ( Figure 4D ) along with its downstream target genes Pik3r1, Igfbp5, Mxd4 and Cdkn1b in the SC-like stage (as illustrated in Figure 4B ). In addition, miR-206 appears to work together with miR-17 in affecting the Stat3 pathway, targeting the Stat3 downstream factor Mxd4 ( Figure 4B ). Dnmt1, a repressor of Stat3 and Stat1, is highly expressed in the SC-like stage, but appears to be targeted by miR-152 and miR-148a upon differentiation, thus allowing the upregulation of Stat transcripts. We predict that the expression of miR-17 and miR-206, and the lack of expression of miR-152 and miR-148a, are important in maintaining the low transcript levels of the Stat pathway-associated genes in undifferentiated HC11 cells. These novel correlations can help to define future functional studies that will need to be performed for miRNAs identified in this study.
A miRNA targeted 152-gene profile delineated good-and poor-prognosis patients
Deregulation of developmental and stem cell critical pathways, as exemplified above, is implicated in cancer development. We have previously observed a correlation of HC11 SC-like gene expression and that of basal-like and poor-prognosis breast tumors (14) . To explore the relation between the set of miRNAs identified and poor-prognosis breast cancer, we first used unsupervised clustering between the HC11 SC-like gene expression profile and that of 258 patients' primary and untreated breast cancer tumors ( Figure 5A ). 
miRNAs in mammary cell differentiation
Tumors clustering with the HC11 SC-like gene expression profile showed significantly lower survival (P 5 0.009) as shown in Figure 5B . These tumors also showed a significantly higher rate of distant metastases (P 5 0.007) and of higher grade tumors (P 5 7  10 −14 ), Table I . This further supports the correlation between this model of SC-like gene expression and that of poor-prognosis breast cancer. We focused on the 152-gene profile that delineated goodand poor-prognosis patient clusters (yellow frame in Figure 5A ) and evaluated this profile in its biological context. Here, the Hedgehog pathway (P 5 3  10 −6 ), and the subnetworks of Melk (P 5 0.00007), FoxM1 (P 5 3  10 −5 ) and the E2F pathway (P 5 4  10 −29 ) were significantly overrepresented (Supplementary Table 4 , available at Carcinogenesis Online). These pathways are all implicated in both stem cell and breast cancer biology. We further investigated this 152-gene profile for miRNA regulation and found that 11 genes were predicted targets of miRNAs implicated in the HC11 SC-like differentiation (Supplementary Table 5 , available at Carcinogenesis Online). Five (E2F1, E2F7, Cdc7, Cdc25A, Dnmt1) out of the eleven genes (45%) were associated with the E2F pathway. The importance of the E2F pathway in breast cancer is supported by reports of elevated E2F activity in basal-like breast tumors (36) . Our findings suggested that the E2F pathway is the primary pathway shared between undifferentiated HC11 cells and poor-prognosis tumors, and a main target for differentiation-induced miRNAs in mammary cells. E2F1 is known as an oncogenic transcription factor that activates genes necessary for tumor cell proliferation (37) . We also note that the stem cell-related factor Serpine1 is transcriptionally regulated by three E2F-regulated transcription factors (Myc, Etv4, Nr4a1/ Nur77) ( Figure 4A ). Thus, we have identified that the E2F pathway is a common characteristic between the undifferentiated HC11 cells and that of poor-prognosis tumors and propose that this pathway is targeted by miRNA during mammary differentiation. These data imply that miRNAs targeting the E2F pathway may be indicative of a good prognosis in breast cancer patients and may be investigated for future biomarker and therapeutic applications.
An identified set of miRNAs can differentiate between human nontumor and breast cancer cells
Since the identified miRNAs are implicated in breast cancer, we proceeded to analyze their levels in human breast cancer cell lines of different tumor subtypes. We found that 6 of the 17 differentiationinduced miRNAs could differentiate between cancer and noncancerous cell lines, and an additional four miRNAs were specifically downregulated in triple-negative breast cancer cells. let-7c, miR27b, miR-22, miR-143, miR-30b and miR-30d showed significantly decreased expression levels in all breast cancer cell lines (ERα-positive MCF-7 and T47D and triple-negative MDA-MB-231) compared with non-tumorigenic epithelial MCF-10A cells ( Figure 6A ). Low let-7 expression has been previously associated with cancer (38, 39) and let-7 miRNA has been defined as a tumor suppressor (39) . Several of the remaining miRNAs have as yet unknown functions in breast cancer. The shared miRNA signature presented here implies conserved and related functions of these six miRNAs in murine mammary development and human breast cancer. A second group of miRNAs (miR-200a, miR-200b, miR-146b and miR-148a) was significantly downregulated in the triple-negative MDA-MB-231 cells, compared with both the non-tumorigenic MCF10A and the ERα-positive breast cancer cell lines ( Figure 6B ). Interestingly, these include two of the three miRNAs predicted in targeting the E2F pathway that is active in poor-prognosis and metastatic breast cancer, miR-200b and miR148a. Our findings suggest that the absence of miR-200a, miR-200b, miR-146b and miR-148a specifically correlates with triple-negative breast cancer markers and hence their therapeutic delivery may constitute a future approach.
Discussion
In this study, we have identified a set of miRNAs with potential roles in mammary differentiation, stem cell maintenance, breast carcinogenesis, as well as for clinicopathological parameters and breast cancer survival. We show that their expression patterns can distinguish between cell lines of different breast cancer subtypes. Furthermore, we show that miR-200a and miR-200b can inhibit EMT characteristics in the HC11 undifferentiated cells, and that miR-200a mediates downregulation of the important breast oncogenic receptor, EphA2. Our data sheds light on the roles of miRNAs and their networks in the maintenance of an undifferentiated phenotype, during induction of differentiation, and in breast carcinogenesis.
Our primary aim was to study the involvement of miRNA in the mammary differentiation program, and we found many correlations to known stem cell mechanisms in the process. The exact identity of mammary stem cells is not fully known, and no markers exist that can distinguish between mammary stem cells and the common progenitor cells (40) . Our study highlights miRNAs involved in 
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the differentiation process, several of which may also participate in maintaining an undifferentiated state. As HC11 cells stop proliferating during functional differentiation, these miRNAs may also be involved in the regulation of proliferation. However, we identified the majority of miRNA regulations at the transition from an undifferentiated state into a committed, and still proliferating, predifferentiated stage. We could also identify characteristic expressions of these miRNAs in different human cell lines, all of which are proliferating. Therefore, we do not expect that the primary role of these miRNAs is to affect proliferation.
We found miR-200a to be the most strongly upregulated miRNA during differentiation, and also that a second member of the same family, miR-200b, was strongly induced. A third member, miR-200c, that is known as a potential molecular link between breast CSCs and normal mammary stem cells (8) , was, however, not differentially expressed in our study. (42) . Several studies have also shown that basal-like tumors share many features with undifferentiated mammary cells (14, 43) . It is thus possible that the differential miRNA expressions between the cell lines are reflective of such differences in cell origin. They may also reflect different levels of differentiation of the cell lines. It is interesting to note that three out of these four miRNAs specifically downregulated in the triple-negative cell line (miR-200a, miR-146b and miR-148a) showed the most significant upregulation (>50-fold) during HC11 differentiation ( Figure 2B ) and that two were further implicated in targeting the poor-prognosis E2F pathway. A second group of miRNAs was downregulated in all three breast cancer cell lines compared with non-tumorigenic mammary epithelial cells ( Figure 6A ), and we speculate that these might be useful candidates for breast cancer marker evaluation.
Our data suggest that the E2F activity is imperative for the similarities between the undifferentiated SC-like HC11 cells and that of poor-prognosis breast cancer. We have previously proposed that HC11 cells resemble the precursor cells for basal-like breast cancer and may provide a suitable model for understanding basal-like breast cancer and its potential relation and conversion from normal stem or progenitor cells. A related observation was made in other studies that found a correlation between gene expression of enriched human stem cells from mammospheres with undifferentiated breast cancer tumors (43) . In the present study, we observed lower survival rates for breast cancer patients whose tumors exhibited an SC-like profile, and that the E2F pathway was implicated. This pathway was also specifically targeted by differentiation-induced miRNAs. We predict that these miRNAs will be downregulated in poor-prognosis, basal-like tumors. Indeed, we could show that the miRNAs targeting the E2F pathway, miR-200b and miR-148a, were selectively downregulated in a basal-like, metastatic breast cancer cell line. The E2F pathway is one of several EGF-induced signal transduction cascades. HC11 cells require EGF treatment to maintain their undifferentiated SC-like phenotype. EGF has also been shown to convert neurogenic precursors in the adult brain into multipotent stem cells, indicative of an involvement in stem cell maintenance (44). We note that the major change in miRNA expression occurred in the transition between the SC-like stage and the committed predifferentiated stage (Figure 2A, B) , not between committed and fully differentiated cells. The predifferentiated stage is induced by EGF withdrawal ( Figure 1A) . Consequently, we speculate that EGF withdrawal may induce the cascades regulating these miRNAs. The differential expression of miRNAs was further enhanced during the second transition, from predifferentiated to fully differentiated cells (Figure 2A, B) , without any additional changes in EGF levels. As mentioned above, the miRNAs that may be induced as a result of EGF withdrawal, in turn downregulate the EGF-E2F pathway. Thus, it is plausible that EGF withdrawal induces regulations of miRNAs, which attenuate the remaining EGF cascade activity in a feedforward loop. Most basal-like tumors have high EGF signaling (45) . EGF signaling and its downstream pathways may be the common denominator between the HC11 SC-like cells and basal-like breast tumors, and potentially, between mammary stem or progenitor cells and breast CSCs. 
Conclusions
This study identifies distinct changes in miRNA expression during differentiation of mammary SC-like cells. By assembling transcriptome analysis and miRNA expression data with predicted targets and pathway information, an intricate gene regulation network emerged. We demonstrate that the miRNA targeted pathways are conserved in poorprognosis breast cancers and show that these miRNAs are also differentially expressed in human breast cancer cells. We show that miR-200a and miR-200b inhibit EMT characteristics in the undifferentiated, non-tumorigenic HC11 cells and that miR-200a mediates repression of EphA2. Candidate miRNAs are identified, which we propose should be further studied to define their clinical utilization. We anticipate that elucidating their roles and pathways in mammary stem cells and in breast cancer will help drive the development of new biomarkers and new therapeutic miRNA approaches for breast cancer treatment.
